New Delhi: Covaxin, made in India, has shown 77.8 percent efficacy in Phase 3 trial data reviewed by the Subject Expert Committee (SEI) of the Drug Controller General of India (DCGI) against coronavirus. Bharat Biotech made a presentation on Tuesday in which data was presented to the panel, which showed 77.8% efficacy of Covaxin.
Indigenous vaccine Covaxni is one of the three vaccines being used to vaccinate people against corona in the country. In April this year, Bharat Biotech said that according to the interim analysis results of Phase III, Covaxin is 78 percent effective against mild, moderate and severe cases of COVID-19.
Read also: Supreme Court nod to CBSE, ICSE Class 12 assessment schemes
The Hyderabad-based vaccine maker has come under sharp criticism for the delay in releasing the Phase III clinical trial of the vaccine. DCGI approved Covaxine for emergency use in India in January based on its Phase 1 and 2 clinical trials.
